FY2025 · ended Dec 31, 2025 · Revenue $11.51M, -1.5% YoY · Filed Apr 7, 2026
Jaguar Health, Inc. (JAGX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $11.5 million and a net loss of $53.6 million. As of Jun 30, 2026 it held $3.8 million in cash and investments and $1.1 million in total debt.
Revenue (TTM)
$27.82M
Net income (TTM)
$-36.92M
+10.8% vs year-ago TTM
Operating cash flow (TTM)
$-6.68M
+75.8% vs year-ago TTM
Free cash flow
$-29.40M
+11.4% vs prior year
EPS (TTM)
$-20.17
-144.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
168.32M
+1101.6% vs prior year
Net cash
$2.70M
as of Jun 30, 2026
Operating margin
-93.1%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JAGX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1585608
- Former names
- Jaguar Animal Health, Inc. (until Jul 31, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2022 Dec 31, 2022 |
FY 2020 Dec 31, 2020 |
FY 2019 Dec 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $11.5M | $11.7M | $12.0M | $9.4M | $5.8M |
| Operating income | -$45.9M | -$30.8M | -$34.4M | -$26.6M | -$28.9M |
| Net income | -$53.6M | -$38.5M | — | -$33.8M | -$38.5M |
| Diluted EPS | -$22.97 | -$130.69 | -$36.18 | — | — |
| Operating cash flow | -$23.7M | -$29.4M | -$33.1M | -$15.3M | -$20.5M |
| Free cash flow | — | -$29.4M | -$33.2M | -$15.3M | — |
| Total assets | $38.3M | $53.4M | $47.5M | $42.8M | $36.4M |
| Total liabilities | $57.0M | $44.4M | $48.8M | $25.6M | $15.8M |
| Stockholders' equity | -$18.7M | $6.5M | -$1.4M | — | — |
| Cash and investments | $968,000 | $8.0M | $5.5M | $8.1M | $3.5M |
| Total debt | $1.1M | $985,000 | $1.2M | — | $337,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 3, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Other events
|
Oct 28, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Material agreement, New debt, Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure, Other events
|
Oct 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Sep 28, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, Unregistered share sale, Other events
|
Sep 25, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Sep 24, 2026 | Sep 23, 2026 |
All 1004 Jaguar Health, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.